Page 13 - Sun Pharma

Sun Pharma extends gains post September quarter earnings; up 6% in two days

The management said the strong revenue and margins were driven by market share gain in India, sustained ramp-up of the company's global specialty business and growth in Emerging Markets

Pharma shares may turnaound soon; Cipla, Sun Pharma, Granules can gain 20%

What do expect from pharma stocks over the next few weeks? Here's what technical charts suggest.

Sun Pharma gains 2%, conquers Rs 1,000-mark after gap of over 7 years

The stock traded higher for the third straight day and has gained nearly 4 per cent during the period. It quoted at its highest level since May 2015.

Nifty500: 248 stocks have more upside; Sun Pharma, RITES 'overbought'

Sun Pharmaceutical Industries is the only other stock among the Sensex 30 and Nifty 50 that trades in the overbought category, technically.

Supreme Court rejects plea by Hero MotoCorp for full budgetary support

But suggests GST Council, states consider mechanism for reimbursing eligible units

Suzlon Energy looks to pare debt by Rs 583.5 crore after rights issue

Targets repaying remaining debt in eight years; Rs 1,200 crore opened on Tuesday

Nifty Pharma index surpasses 200-DMA; Cipla, Granules can soar up to 15%

The Pharma benchmark has outperformed the overall market in recent trading sessions; sustenance above 200-DMA is likely to trigger further gains for it

Nifty Pharma outshines benchmarks, up 2%; Cipla, Sun Pharma hit 52-wk highs

Shares of Glenmark Pharma, Granules India, Divi's Laboratories, Torrent Pharma, Lupin and Aurobindo Pharma, surged in the range of 2 per cent to 6 per cent in Monday's intra-day trade

LIC, Nykaa, Tata Motors: Are these buzzing stocks bottoming out?

Sun Pharmaceutical seems set to register a new 52-week high; while Tata Motors and Torrent Pharmaceuticals are yet to take-off their respective obstacles, charts show.

Sun Pharma extends rally, surges 7% in two days; now trades at 5-month high

Sun Pharma could see structural growth and be relatively insulated from the adverse price erosion scenario in the US, according to analysts.

Rise of cosmetic dermatology space gets big pharma looking for buyouts

According to reports, Torrent Pharmaceuticals is set to sign a deal to acquire Curatio Healthcare, a maker of skincare products, for Rs 2100 crore.

Specialty drugs may push Sun Pharma's US biz beyond $2 bn by 2025

The share of specialty medicines in overall pharmaceutical spending has been consistently increasing over the past decade, from 22 per cent in 2011 to 39 per cent in 2021

Six-day work weeks won't work anymore for new talent, says report

According to a report, companies with 6-day work weeks have to settle for leftover talent

Drug makers Glenmark, Sun Pharma, Dr Reddy's recall products in US

Leading generic drug makers Glenmark, Sun Pharma, Dr Reddy's and Jubilant Cadista are recalling multiple products in the US market, the world's largest market for medicines, for various issues

Sun Pharma stock likely to keep shining amid global specialty scale-up

Focus on key markets to help expand branded formulations business, say experts

We continue to increase our reach and access in India, say Sun Pharma execs

Senior Sun Pharma executives speak on a two-pronged strategy for the China market, beginning R&D of biosimilar products, and more

Sun Pharma Q1 net up 43% to Rs 2,061 crore on specialty sales, India biz

Gross sales up 10.1% YoY to Rs 10,644 cr; EBITDA at Rs 2,884.4 cr, with a margin of 26.8%

Sun Pharma shares jump over 5% after firm's Q1 net profit rises 43%

Shares of Sun Pharma on Friday jumped over 5 per cent after the company reported a 43 per cent rise in consolidated net profit for the June quarter. The stock climbed 5.45 per cent to settle at Rs 943.55 apiece on the BSE. During the day, it rallied 6.31 per cent to Rs 951.25. On the NSE, it jumped 5.44 per cent to Rs 943.60 apiece. In volume terms, 4.88 lakh shares were traded on the BSE and over 1.13 crore shares on the NSE during the day. On Friday, Sun Pharma reported a 43 per cent rise in consolidated net profit at Rs 2,061 crore for the June quarter, riding on robust sales across markets. The Mumbai-based company had posted a net profit of Rs 1,444 crore in April-June period of 2021-22. Total revenue from operations rose to Rs 10,762 crore in the period under review from Rs 9,719 crore earlier, Sun Pharmaceutical Industries said in a regulatory filing. The 30-share BSE barometer jumped 712.46 points or 1.25 per cent to settle at 57,570.25.

Top headlines: HDFC Q1 net rises 22%; IOC posts Rs 1,993-cr net loss in Q1

Swiggy announced on Friday that it has extended its 'Future of Work' policy and announced a permanent work-from-anywhere for majority of roles.

Sensex rises 712 pts, Nifty tops 17,150; Tata Steel rallies 7%, HDFC 2%

CLOSING BELL: Public sector banks were the only losers with the Nifty PSB index down 1.2 per cent